9 research outputs found
Copy Number Gains of the Putative CRKL Oncogene in Laryngeal Squamous Cell Carcinoma Result in Strong Nuclear Expression of the Protein and Influence Cell Proliferation and Migration
Laryngeal squamous cell carcinoma is a major medical problem worldwide. Although our understanding
of genetic changes and their consequences in laryngeal cancer has opened new therapeutic pathways
over the years, the diagnostic as well as treatment options still need to be improved. In our previous
study, we identifed CRKL (22q11) as a novel putative oncogene overexpressed and amplifed in a subset
of LSCC tumors and cell lines. Here we analyze to what extent CRKL DNA copy number gains correlate
with the higher expression of CRKL protein by performing IHC staining of the respective protein in
LSCC cell lines (n=3) and primary tumors (n=40). Moreover, the importance of CRKL gene in regard to
proliferation and motility of LSCC cells was analyzed with the application of RNA interference (siRNA).
Beside the physiological cytoplasmic expression, the analysis of LSCC tumor samples revealed also
nuclear expression of CRKL protein in 10/40 (25%) cases, of which three (7.5%), presented moderate or
strong nuclear expression. Similarly, we observed a shift towards aberrantly strong nuclear abundance
of the CRKL protein in LSCC cell lines with gene copy number amplifcations. Moreover, siRNA mediated
silencing of CRKL gene in the cell lines showing its overexpression, signifcantly reduced proliferation
(p<0.01) as well as cell migration (p<0.05) rates. Altogether, these results show that the aberrantly
strong nuclear localization of CRKL is a seldom but recurrent phenomenon in LSCC resulting from the
increased DNA copy number and overexpression of the gene. Moreover, functional analyses suggest
that proliferation and migration of the tumor cells depend on CRKL expression.</p
Recurrent epigenetic silencing of the PTPRD tumor suppressor in laryngeal squamous cell carcinoma
Cellular processes like differentiation, mitotic cycle, and cell growth are regulated by tyrosine kinases with known oncogenic potential and tyrosine phosphatases that downmodulate the first. Therefore, tyrosine phosphatases are recurrent targets of gene alterations in human carcinomas. We and others suggested recently a tumor suppressor function of the PTPRD tyrosine phosphatase and reported homozygous deletions of the PTPRD locus in laryngeal squamous cell carcinoma. In this study, we investigated other gene-inactivating mechanisms potentially targeting PTPRD, including loss-of-function mutations and also epigenetic alterations like promoter DNA hypermethylation. We sequenced the PTPRD gene in eight laryngeal squamous cell carcinoma cell lines but did not identify any inactivating mutations. In contrast, by bisulfite pyrosequencing of the gene promoter region, we identified significantly higher levels of methylation (p = 0.001 and p = 0.0002, respectively) in 9/14 (64%) laryngeal squamous cell carcinoma cell lines and 37/79 (47%) of primary laryngeal squamous cell carcinoma tumors as compared to normal epithelium of the upper aerodigestive tract. There was also a strong correlation (p = 0.0001) between methylation and transcriptional silencing for the PTPRD gene observed in a cohort of 497 head and neck tumors from The Cancer Genome Atlas dataset suggesting that DNA methylation is the main mechanism of PTPRD silencing in these tumors. In summary, our data provide further evidence of the high incidence of PTPRD inactivation in laryngeal squamous cell carcinoma. We suggest that deletions and loss-of-function mutations are responsible for PTPRD loss only in a fraction of cases, whereas DNA methylation is the dominating mechanism of PTPRD inactivation.</p
Combined deletion and DNA methylation result in silencing of FAM107A gene in laryngeal tumors
Larynx squamous cell carcinoma (LSCC) is characterized by complex genotypes, with numerous abnormalities in various genes. Despite the progress in diagnosis and treatment of this disease, 5-year survival rates remain unsatisfactory. Therefore, the extended studies are conducted, with the aim to find genes, potentially implicated in this cancer. In this study, we focus on the FAM107A (3p14.3) gene, since we found its significantly reduced expression in LSCC by microarray profiling (Affymetrix U133 Plus 2.0 array). By RT-PCR we have confirmed complete FAM107A downregulation in laryngeal cancer cell lines (15/15) and primary tumors (21/21) and this finding was further supported by FAM107A protein immunohistochemistry (15/15). We further demonstrate that a combined two hit mechanism including loss of 3p and hypermethylation of FAM107A promoter region (in 9/15 cell lines (p p FAM107A expression (5 to 6 fold increase) in the UT-SCC-29 cell line, characterized by high DNA methylation. Therefore, we report the recurrent inactivation of FAM107A in LSCC, what may suggest that the gene is a promising tumor suppressor candidate involved in LSCC development.</p